Company search
Biotechnology & Healthcare: a sector on the mend?
What’s the prognosis for biotech and healthcare companies? How will the US election impact the sector, and could we see a recovery later this year?
Overview
Performance
Portfolio
ESG
Dividends
Charges
Gearing
Research
Announcements
Management
Documents
Invest
Research
Kepler Trust Intelligence
21 March 2024
Ailsa Craig and Marek Poszepczynski are celebrating their first three years as managers of IBT.
Related articles
Top performing investment trust ISAs over the last 25 years
18 trusts returned over £100,000 from a one-off £7,000 investment.
Who wants to be an ISA millionaire?
Ian Cowie dives into the investment trusts that would have made you over £1,000,000.
Related videos
Biotechnology & Healthcare: what are the challenges of investing in the sector?
Annabel Brodie-Smith asks managers about the challenges of investing in the Biotechnology & Healthcare sector.
Biotechnology & Healthcare: where are you finding opportunities?
A panel of Biotechnology & Healthcare managers discuss where they are currently finding opportunities.
Biotechnology & Healthcare: is the sector due a comeback?
Annabel Brodie-Smith, Brett Darke, Marek Poszepczynski and Geoff Hsu discuss whether Biotechnology & Healthcare is due a comeback.
Biotechnology & Healthcare: will the results of the US election make a difference for the sector?
Brett Darke, Marek Poszepczynski and Geoff Hsu on whether the results of the next US election will impact the Biotechnology & Healthcare sector.
Related Industry News
Int’l Biotechnology: Why we turn over all our stocks once a year
International Biotechnology Trust fund manager Ailsa Craig explains why there is a high level of stock turnover in the portfolio.
Ailsa Craig: Big pharma has a problem and that’s driving biotech M&A
Co-manager of International Biotechnology Trust shows how the expiry of patents is forcing big pharmaceutical companies to buy drug developers.
Schroders: Look at what US bond yields are doing, then watch biotech!
Biotech stocks and US govt bond yields tend to move in opposite directions, which is very interesting right now, says Marek Poszepczynski of International Biotechnology Trust.
Int’l Biotechnology: Why investors are moving back to our recession-beating sector
Interest rate pressures are easing on biotechnology, allowing the strong fundamentals of drug development to shine, say International Biotechnology Trust fund managers Ailsa Craig and Marek Poszepczynski.
Investment company news brought to you by Citywire Financial Publishers Limited
and QuotedData by Marten & Co.
Data provided by Morningstar.
Company documents provided by FE fundinfo.
